Summary
THREE of Ireland's top biotech companies yesterday had a day of mixed fortunes. Athlone-based drug developer Elan announced that more than 43,300 patients have been treated with the multiple sclerosis drug Tysabri in the two years since it was reintroduced to the market.
More than 31,800 patients worldwide are currently receiving Tysabri treatment.See the full content of this document
Extract
Mixed Fortunes for Biotech Businesses
Meanwhile, Trinity Bio...
See the full content of this document
Sponsored links
